Evidence Hub

The effectiveness of combined oral pentoxifylline, colchicine, and tadalafil therapy for the treatment of peyronie’s disease

M. Dursun, Ş. Şenel, M. Gurcan, A. Aydinoğlu, A. Sevinc, A. Kadioglu

Journal of Sexual Medicine, 2025

160 participants

Abstract

Abstract Objectives In the medical treatment of Peyronie’s disease (PD), various agents and their combinations continue to be used. However, there is no standardized treatment. The expectation from an effective treatment agent is that it leads to the regression of the fibrotic plaque and penile curvature and improves the patient’s sexual life. The present study aims to determine the effect of the combination of colchicine, pentoxifylline and tadalafil in the acute phase of PD. Methods Retrospective data of patients who presented with acute phase PD between 2004-2024 and received combined medical treatment (tadalafil 5 mg once a day + pentoxifylline 400 mg twice a day + colchicine 0.5 mg twice a day) were analyzed. Results Average age of the 160 participants was 53.7 ± 9.7 years. The median curvature degree was 35° (IQR: 30-45°). Prior to treatment, 59 (36.9%) patients had penile pain and 87 (54.4%) patients had concomitant ED. At the posttreatment evaluation, median curvature degree was 30° (IQR: 15-45°). Out of the curvatures at the pretreatment period, 7 (4.4%) disappeared, 23 (14.4%) regressed and 72 (45%) remained stable. 34 (57.6%) of 59 patients with penile pain experienced improvement in their symptom. Risk factors for curvature progression after combined medical treatment were evaluated with logistic regression analysis. Only smoking habit (OR = 4.851; 95% CI = 2.164–9.695; p < 0.001) was stated as a risk factor for progression. Conclusions The combination of oral…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free